Studies on the inhibition of feline EGFR in squamous cell carcinoma Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors

This study investigated different methods of eGFR (epithelial growth factor receptor) targeting in feline squamous cell carcinoma with the ultimate aim of establishing a large animal model of human head and neck cancer. Both small molecule receptor tyrosine kinase inhibitor (TKI) and RN a interference (RNai) techniques were employed to target the feline eGFR. We demonstrated that the human drug gefitinib caused a reduction in cell proliferation and migration in a feline cell line. however, we also document the development of resistance that was not associated with mutation in the kinase domain. RN ai caused a potent reduction in e GFR activity and was able to overcome acquired gefitinib resistance. In addition, RNai targeting of eGFR, but not gefitinib, caused an additive effect on cell killing when combined with radiation. These results support the use of feline s CC as a model of head and neck cancer in man in the search for novel and effective treatments for both tumors.